Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Temiverine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.69 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.69 |
| ▸ | CHRM4 known ✓ | P08173 | 5/20 | 0.69 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.69 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.69 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.69 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.69 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.69 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.69 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.69 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.69 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.69 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.69 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.69 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.69 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temiverine SCHEMBL5592324 | 0.99 | MEN1 (0.70) | MEN1RECQLPMP22KMT2ANPSR1 | |
| Hydrochloric Acid SCHEMBL9878351 | 0.99 | MEN1 (0.69) | MEN1RECQLPMP22KMT2ANPSR1 | |
| Temiverine SCHEMBL120687 | 0.99 | CHRM2 (0.70) | MEN1RECQLPMP22KMT2ANPSR1 | |
| Temiverine SCHEMBL896437 | 0.99 | CHRM2 (0.70) | MEN1RECQLPMP22KMT2ANPSR1 | |
| Temiverine SCHEMBL6816326 | 0.98 | CHRM2 (0.69) | MEN1RECQLPMP22KMT2ANPSR1 | |
| Temiverine SCHEMBL1650105 | 0.97 | CHRM2 (0.68) | MEN1RECQLPMP22KMT2ANPSR1 | |
| Hydrochloric Acid SCHEMBL9878913 | 0.92 | POLB (0.61) | MEN1RECQLPMP22KMT2ANPSR1 | |
| Hydrochloric Acid SCHEMBL9878732 | 0.90 | POLB (0.59) | MEN1RECQLPMP22KMT2ANPSR1 | |
| SCHEMBL7274104 | 0.86 | CHRM2 (0.54) | MEN1RECQLPMP22KMT2ANPSR1 | |
| SCHEMBL9618325 | 0.85 | POLB (0.54) | MEN1RECQLPMP22KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915992-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007072503-A2 | COMBINATIONS FOR MANAGING INFLAMMATION AND ASSOCIATED DISORDERS | PANACEA BIOTEC LTD. (IN) | 2007-06-28 | — | — | WO | claimed |
| CN-1633283-A | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence | PHARMACIA CORP (US) | 2005-06-29 | — | — | CN | claimed |
| EP-1476146-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2004-11-17 | — | — | EP | claimed |
| US-20030220310-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2003-11-27 | — | — | US | claimed |
| US-20030220312-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| US-20030191172-A1 | Method of using cyclooxygenase inhibitors and antimuscarinic agents | VERSI EBRAHIM (US) | 2003-10-09 | — | — | US | claimed |
| WO-2003070233-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | PHARMACIA CORPORATION (US) | 2003-08-28 | — | — | WO | claimed |
| WO-2002009761-A9 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORP (US) | 2003-07-10 | — | — | WO | claimed |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 2003-03-20 | — | — | US | claimed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | claimed |
| EP-0359311-B1 | Butynylamine derivatives | NIPPON SHINYAKU CO LTD (JP) | 1997-01-15 | — | — | EP | claimed |
| US-5036098-A | Urogenital disorders | NIPPON SHINYAKU CO., LTD. (JP) | 1991-07-30 | — | — | US | claimed |
| EP-4744688-A2 | DRUG DELIVERY DEVICES WITH DRUG-PERMEABLE COMPONENT AND METHODS | Janssen Biotech, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3285850-B1 | DRUG DELIVERY DEVICES WITH DRUG-PERMEABLE COMPONENT AND METHOD OF MANUFACTURING | JANSSEN BIOTECH INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12576253-B2 | Drug delivery device with intravesical tolerability | TARIS BIOMEDICAL LLC (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2002009761-A9 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORP (US) | 2003-07-10 | — | — | WO | disclosed |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 2003-03-20 | — | — | US | disclosed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | disclosed |
| US-5036098-A | Urogenital disorders | NIPPON SHINYAKU CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220312-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders | NR3C2, PTGER4, PTGER1 | CHRM2 1932/4885CHRM1 1610/4885CHRM4 1124/4885 |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | PTGER1, KCNN4, HCN1 | CHRM2 467/4885CHRM1 226/4885CHRM4 415/4885 |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | KCNN4, NR3C2, EDNRA | CHRM2 594/4885CHRM1 533/4885CHRM4 433/4885 |
| US-20030191172-A1 | Method of using cyclooxygenase inhibitors and antimuscarinic agents | PTGS2, PTGES2, PTGS1 | CHRM2 7/4885CHRM1 26/4885CHRM4 34/4885 |
| US-12576253-B2 | Drug delivery device with intravesical tolerability | ABCB11, SLC6A6, SLC10A2 | CHRM2 3492/4885CHRM1 3858/4885CHRM4 4423/4885 |
| US-20030220310-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | KCNN4, NR3C2, EDNRA | CHRM2 594/4885CHRM1 533/4885CHRM4 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.